A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells
Open Access
- 12 May 2020
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 10 (10), 3364
- https://doi.org/10.3390/app10103364
Abstract
Targeted therapy has become the preferred approach to treat most cancers, including metastatic breast cancer. Using liquid biopsies, which can act as a dynamic diagnostic tool, is an appealing concept to identify effective therapies. In order to identify mutations from circulating tumor cells (CTCs) on single cell level, we have developed a multiplex PCR-based next generation sequencing-panel. The CTCs were enriched using the CellSearch system and isolated by micromanipulation followed by whole genome amplification of their DNA. Afterwards, mutation hotspot regions in the PIK3CA, the ESR1, the AKT1, and the ERBB2 genes were amplified and barcoded. Sequencing was performed on a MiSeq system. The assay was validated with cells from various cell lines displaying the expected mutations. Mutations that provide the basis for potential targeted therapies were detected in 10 out of 13 patients in all analyzed genes. In four patients, mutations in more than one gene were observed—either in the same cell or in different cells, suggesting the presence of different tumor cell clones, which might be targeted with combination therapies. This assay is a time and cost effective tool to investigate the most relevant genomic positions indicative for targeted therapies in metastatic breast cancer. It can support therapy decision to improve the treatment of cancer patients.This publication has 35 references indexed in Scilit:
- Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create MetastasisCancers, 2013
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and explorationBriefings in Bioinformatics, 2012
- Circulating tumor cells: approaches to isolation and characterizationThe Journal of cell biology, 2011
- Circulating tumour cells in cancer patients: challenges and perspectivesTrends in Molecular Medicine, 2010
- Oncogenic Mutations of PIK3CA in Human CancersPublished by Springer Science and Business Media LLC ,2010
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences of the United States of America, 2008
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceEndocrine Reviews, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutralJournal of Medical Genetics, 2005
- Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant DiseasesClinical Cancer Research, 2004